OOIR: Observatory of International Research

Papers

(The H4-Index of American Journal of Clinical Dermatology is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Rosacea: New Concepts in Classification and Treatment	114
Sunscreens and Photoaging: A Review of Current Literature	114
Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review	113
Pyoderma Gangrenosum: An Updated Literature Review on Established and Emerging Pharmacological Treatments	106
Psychosocial Effects of Vitiligo: A Systematic Literature Review	103
Cutaneous Leishmaniasis: A 2022 Updated Narrative Review into Diagnosis and Management Developments	87
Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program	79
Erythema Nodosum: A Practical Approach and Diagnostic Algorithm	78
Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study	78
Ceramides in Skin Health and Disease: An Update	72
Treatment Options and Goals for Patients with Generalized Pustular Psoriasis	71
Clinical Course and Characteristics of Generalized Pustular Psoriasis	66
Pathophysiology of Generalized Pustular Psoriasis	66
Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review	65
Dermatitis Herpetiformis: An Update on Diagnosis and Management	62
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis	54
Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE)	54
Granuloma Annulare: An Updated Review of Epidemiology, Pathogenesis, and Treatment Options	51
The Growing Problem of Antifungal Resistance in Onychomycosis and Other Superficial Mycoses	51
New Practical Aspects of Sweet Syndrome	50
Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study	48
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies	46
Deucravacitinib for the Treatment of Psoriatic Disease	40
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)	40
New Onset and Exacerbations of Psoriasis Following COVID-19 Vaccines: A Systematic Review	40

50 Years of Topical Retinoids for Acne: Evolution of Treatment	39
Teledermatology During COVID-19: An Updated Review	38
Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma	36
The Prevalence and Disease Characteristics of Generalized Pustular Psoriasis	35
Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial	35
Effects of Topical Retinoids on Acne and Post-inflammatory Hyperpigmentation in Patients with Skin of Color: A Clinical Review and Implications for Practice	35
Impact of Generalized Pustular Psoriasis from the Perspective of People Living with the Condition: Results of an Online Survey	35
Clinical Disease Measures in Generalized Pustular Psoriasis	35
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study	33
The Importance of Incorporating Human Factors in the Design and Implementation of Artificial Intelligence for Skin Cancer Diagnosis in the Real World	33
Investigational Treatments for Epidermolysis Bullosa	33
Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials	33